Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UVADEX with THERAKOS CELLEX photopheresis in pediatric steroid-refractory acute graft-versus-host disease
2014-004806-14Phase 3Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of methoxsalen in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: Overall response at 4 weeks. Started Sep 2015; status: completed.
02
Drugs
methoxsalen
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2014-004806-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004806-14.